Log In
Print this Print this

Pulmaquin, Liposomal ciprofloxacin (ARD-3150)

  Manage Alerts
Collapse Summary General Information
Company Aradigm Corp.
DescriptionDual release product consisting of liposomal-encapsulated form of ciprofloxacin, a DNA gyrase inhibitor, mixed with a solution of free ciprofloxacin for inhalation
Molecular Target DNA gyrase
Mechanism of ActionProkaryotic replication inhibitor
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentPhase III
Standard IndicationChronic obstructive pulmonary disease (COPD)
Indication DetailsTreat bronchiectasis (BE); Treat non-cystic fibrosis (CF) bronchiectasis
Regulatory Designation U.S. - Fast Track (Treat non-cystic fibrosis (CF) bronchiectasis);
U.S. - Orphan Drug (Treat bronchiectasis (BE));
U.S. - Qualified Infectious Disease Program (Treat non-cystic fibrosis (CF) bronchiectasis)
Partner Grifols S.A.

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments





 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone
Get a free BioCentury trial today